chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Immediate extreme pain shooting from my shoulder to my elbow. I asked at the waiting area how long the pain was supposed to last and they told me a few weeks.  I couldn't use my arm at all for a few hours and for a few days I couldn't do my hair or dress normally.  For a few weeks I experienced pain and weakness when doing simple tasks like lifting a glass or buckling a seatbelt.  For a few months I have experienced pain when sleeping, jogging, hugging, etc.  My arm now feels weaker than before and I avoid using it on a regular basis because of the pain.  The pain has evolved from being acute and achey all of the time to mostly aching during use or when moved.  Many people initially told me pain was normal would last a few weeks and that I might just be healing slowly.  After 6 weeks, I determined that this was likely not normal to be in such pain.  Now, 3.5 months later, I am really ready to get answers, as the pain and weakness are lingering and don't seem to be completely healing.  My mom, a physical therapist, suspects that the needle might have entered the bursa, and my husband and I have suspected that it might have damaged my rotator cuff.
Redness and swelling noted by mom, the afternoon following DTAP injection. Area was approx. 2" in diameter. Spontaneously resolving now. By the next day, redness gone and swelling decreased.
This is a 72y.o. male with history of atrial fibrillation on Xarelto, SSS with pacemaker, history of DVT, sleep apnea, and recent diagnosis of COVID-19 who presents with left lower quadrant pain in addition to fatigue and cough. His symptoms began about 5 days ago. The patient went to urgent care and he was referred to the ED when he was found to be in atrial fibrillation with RVR. No fever, chills, lightheadedness, chest pain, or palpitations. He denies nausea, vomiting, diarrhea, or constipation. No history of kidney stones. He says he's been compliant with all of his medications. The patient is a former smoker, quit 35 years ago.   On arrival to the ED, RVR confirmed by EKG, HR 126. SpO2 normal on room air. Troponin x 3 negative. D-dimer 1,205. CBC and BMP unrevealing. TSH normal. CT angiogram chest negative for PE, but shows scattered groundglass opacities and multiple pulmonary nodules, largest in the RLL measuring 8 mm. CT abdomen/pelvis revealed acute interstitial pancreatitis and colonic diverticulosis and fatty infiltration of liver. The patient was started on a Cardizem infusion and HR subsequently dropped into the 40's. Cardiology was consulted.
This spontaneous report was received from a nurse prescriber and refers to a 67 year old female patient. The patient did not have any pertinent medical history, drug reactions or allergies. She did not take any concomitant medications. On 11-JAN-2017, the patient was vaccinated with a dose of PNEUMOVAX23 injection (route and site of administration, dose, lot number and expiration date were not reported) for prophylaxis. Since 11-JAN-2017 (reported as "for a week"), the patient was experiencing cough, chills and fever. She complained of these symptoms when she came into the reporter's office on 18-JAN-2017. The patient was treated with albuterol sulfate (PROVENTIL) and betamethasone (CELESTONE), which was reported as an intervention to prevent serious criteria. In February 2017 (reported as "in February"), the patient was diagnosed with pneumonia and Guillain-Barre syndrome. No lab diagnostic studies were performed. Product quality complaint was not involved. The outcome of pneumonia and Guillain-Barre syndrome was reported as not recovered. The relatedness between the events and the vaccination with PNEUMOVAX23 was not reported. No additional information was provided. Upon internal review, pneumonia and Guillain-Barre syndrome were determined to be medically significant. Additional information has been requested.
high blood pressure; body pain; tinnitus; This is a spontaneous report received from a contactable reporter(s) (Pharmacist) from medical information team.  A female patient received BNT162b2 (BNT162B2), as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "psoriasis" (unspecified if ongoing); "fibromyalgia" (unspecified if ongoing). The patient's concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (DOSE 1, MANUFACTURER UNKNOWN), for Covid-19 immunization. The following information was reported: HYPERTENSION (non-serious), outcome "unknown", described as "high blood pressure"; PAIN (non-serious), outcome "unknown", described as "body pain"; TINNITUS (non-serious), outcome "unknown". Relevant laboratory tests and procedures are available in the appropriate section.  Additional information: It was reported that the patient who received 2nd dose of covid vaccine (not sure which formulation of the adult vaccine) had experienced high blood pressure, body pain and tinnitus for 3 weeks.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
pt broke out in hives Thursday 6 hrs p/injections; no other s&s noted; DPH given by ER MD; f/u by MD states hives probably related to vax;
Information has been received from a female registered with ankylosing spondylitis. Who on 21-Nov-2008 was vaccinated with a dose of ZOSTER vaccine (lot # not provided). After vaccination, nurse developed a very large welt, about 3-4 inches in diameter on her left arm. The nurse also experienced swelling, warmth and soreness at the site. The nurse reported that she used cold compresses to reduce swelling of the welt. The area was still red and sore 24-Nov-2008. At the time of reporting (24-Nov-2008) the outcome of the very large welt, swelling and warmth was not reported. Additional information has been requested. Follow-up information has been received from a registered nurse a 46 year old female with ankylosing spondylitis. Who on 21-Nov-2008 was vaccinated with a dose of ZOSTER vaccine (lot #658205/1085U) subsequently. On 10-OCT-2008 the reporter was vaccinated with FLUZONE and pneumococcal vaccine, polyval (MSD). On 22 NOV-2008 the patient developed red, warm at the site, hard induration starting at approximately 3x5 cm increasing to approximately 8x12 cm. painful and itching and had a patch of shingles down the center of the induration. The patient was prescribed with (MEDROL DOSE PACK). On 28-NOV-2008 the patient recovered. Additional information is not expected.
Information has been received from a nurse referring to a patient of unknown age and gender. Information of concomitant therapy, pertinent medical history and drug reactions/allergies was not reported. On 28-SEP-2018, the patient was vaccinated with the first dose of GARDASIL 9 (strength, dose, route, lot number and expiration date were not provided) for prophylaxis. On 12-OCT-2018 (2 weeks after receiving first dose of GARDASIL 9, the patient was vaccinated with a second dose of GARDASIL 9 (lot # R008163, expiration date: 18-NOV-2020, dose and route were unknown) for prophylaxis. No adverse effects were reported. This is one of two linked cases due to same reporter. Sender's Comments: US-009507513-1810USA006713.
10/13/09 MedImmune Flu Mist at 630PM.  C/O dizziness shortly after.  Observation:  VS, P 84, R 20, B/P 130/80:  Color good after having pt rest with cool cloth.  He was able to stand and walk with steady gait.  Refuse - 911 ask to allow friend to be called.
moderate nausea that lasted for like 2 days; This is a spontaneous report received from a non-contactable consumer. The reporter is the patient.  A 27-year-old female patient (not pregnant) received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Solution for injection, Batch/Lot number: unknown) at the age of 27 years as dose 1, single for COVID-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: NAUSEA (non-serious), outcome "recovered", described as "moderate nausea that lasted for like 2 days".  Additional information: The patient experienced the event a day after the first dose.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Day 1 - minor headache, nausea, exhaustion Day 2 - exhaustion, migraine Day 3 - latissimus dorsi pain on same side as injection (L)
Excursion from the freezer; This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (Excursion from the freezer) in a 61-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 939901) for COVID-19 vaccination.     No Medical History information was reported.   On 25-Oct-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 25-Oct-2021, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Excursion from the freezer). On 25-Oct-2021, PRODUCT TEMPERATURE EXCURSION ISSUE (Excursion from the freezer) had resolved.      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No relevant concomitant medications was reported. Treatment information was not provided.   Most recent FOLLOW-UP information incorporated above includes: On 15-Nov-2021: Follow-up received which included patient details (initials, age, gender) and vaccine information ( date of vaccination, dose number).
square patch of redness  (1.25 by 1..25)  symmetric on the left arm where the shot was given.  It is itchy off and on. On Sunday Nov 28, the section  left hard and itchy.  i  did not see the red patch until yesterday Nov 29 2021.
This spontaneous report as received from a medical assistant refers to a patient of unknown age and gender. There was no information about the patient's concurrent conditions, concomitant therapies or medical history provided. On 30-MAY-2018, the patient was vaccinated with an improperly stored dose of PEDVAXHIB, lot # N022167, expiration date: 08-FEB-2020 (dose and route of administration were not reported). There was no adverse effect reported. Administered dose of vaccine experienced the temperature excursion of 47 to 77 degrees Fahrenheit for 5 hours. Data logger was involved. There were no previous excursions reported. This is one of several reports received from the same reporter. Sender's Comments: US-009507513-1806USA001505: US-009507513-1806USA009026: US-009507513-1806USA009027: US-009507513-1806USA009028: US-009507513-1806USA009029: US-009507513-1806USA009030: US-009507513-1806USA009031:US-009507513-1806USA009032: US-009507513-1806USA009033: US-009507513-1806USA009034: US-009507513-1806USA009035: US-009507513-1806USA009036: US-009507513-1806USA009037: US-009507513-1806USA009038: US-009507513-1806USA009039: US-009507513-1806USA009040: US-009507513-1806USA009041: US-009507513-1806USA009042: US-009507513-1806USA009043: US-009507513-1806USA009044: US-009507513-1806USA009045: US-009507513-1806USA009046: US-009507513-1806USA009047: US-009507513-1806USA009048: US-009507513-1806USA009049: US-009507513-1806USA009050: US-009507513-1806USA009051: US-009507513-1806USA009052: US-009507513-1806USA009053: US-009507513-1806USA009055: US-009507513-1806USA009056.
"Tightness in chest, short of breath", dizzy, chills lightheaded, increasing itching at injection site Treatment-O2 at 6 L/min, Aqueous Epinephrine 1:1000, 0.3 cc SQ, Transported to ER in ambulance
I had a break through case of Covid my symptoms were very sore throat then sever coughing, tested on 10/29 indicating positive test then started getting constant headache and cough continued to get worse. I had an ocular Migraine, diarrea, chills and fatige with ache and pressure in my chest.
This spontaneous report as received from a pharmacist refers to a patient of unknown age and gender. No concurrent condition, medical history or allergy/drug reactions were reported. On 20-OCT-2015 13:08, the patient was vaccinated with improperly stored RECOMBIVAX HB with lot number: L016427, expiry date: 13-APR-2017 (dose and strength unspecified). No concomitant medications were reported. No adverse effects were reported. The high temperature and low temperature were 4.3 and -2.1 respectively. There were no product quality complaints (PQC) involved. No additional information was provided. This is one of the several reports from the same reporter. Additional information has been requested.
Vertigo; Loud noises amplified; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 66 year-old male patient received bnt162b2 (BNT162B2), administered in arm right, administration date 13Feb2021 17:00 (Lot number: EP6955) at the age of 66 years as dose 1, single for covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. The following information was reported: VERTIGO (non-serious) with onset 27Feb2021 08:00, outcome "not recovered", described as "Vertigo"; HYPERACUSIS (non-serious) with onset 2021, outcome "not recovered", described as "Loud noises amplified". The events "vertigo" and "loud noises amplified" were evaluated at the physician office visit. Therapeutic measures were not taken as a result of vertigo, hyperacusis.  Additional information: The patient never had an episode of vertigo before. The patient had no known allergies to medications, food, or other products. The patient did not receive any other medications within two weeks prior to the COVID-19 vaccine. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19.  No follow-up attempts are possible. No further information is expected.
Capsulitis of the left shoulder/currently having a shoulder pain and she was got like locked joint in her shoulder; This is a spontaneous report from a contactable consumer. An 84-year-old female patient received pneumococcal 13-valent conjugate vaccine (diphtheria CRM197 protein) (PREVNAR 13, lot number X49147, expiration date 30Nov2020), intramuscular in left deltoid on 29Jan2019 at 0.5 ml, single for preventative measures for the vaccine. Medical history was none. Concomitant medications were not reported. It was reported that the patient was currently having a shoulder pain and she was got like locked joint in her shoulder. She had the capsulitis of the left shoulder, which she was diagnosed with. The patient received diclofenac potassium (VOLTAREN) topical gel but she just started that today with the visit, she had given that for the shoulder pain, so it was just prescribed today. She was also started the physical therapy. It was stated that on 28Mar2019 was her last blood work which included a CMP, CBC and TSH and results were all normal. The reporter further mentioned that there were panels of lab work and it was going to take while to give the original panel. The outcome of the event was unknown.
She was vaccinated on Monday 11/5. The next day she had a fever of 105 and she was taken to an ER. Her arm swelled up and she was seen in our clinic on 11/7 and put on Duracef. Today her temp is 102.8. Has follow-up appt 11/9 but will return sooner if swelling increases
Headache, Myalgia, Fever, Diarrhea,  right arm very sore
Day#0  (about 4 hours after vaccination) - Some chest discomfort, shortness of breath. Day#1 - Still with some chest discomfort, shortness of breath, indigestion, diarrhea. Day#2 - Symptoms much improved.
7 people had  died from Pfizer; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP), Program ID: (RA).  An elderly (reported as "50-99" and "Age Group: Elderly (greater than equal to 65 years)") male patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DEATH (death), outcome "fatal", described as "7 people had  died from Pfizer". The date and cause of death for the patient were unknown. It was not reported if an autopsy was performed.  Clinical course: Age + years/months/days: 50-99. Age Group: Elderly (greater than equal to 65 years). Moderna has proven to be effective against COVID-19; Pfizer is not that effective when the reporter first heard about it. 7 people had died from Pfizer; So that made a change in mind about taking Moderna. Plus, the Primary Care doctor suggested Moderna based of these stories that the reporter heard. The reporter considers the event as caused by the suspect product.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202300276245 Same reporter/event/drug, different patient;US-PFIZER INC-202300276246 Same reporter/event/drug, different patient;US-PFIZER INC-202300276247 Same reporter/event/drug, different patient;US-PFIZER INC-202300276248 Same reporter/event/drug, different patient;US-PFIZER INC-202300276249 Same reporter/event/drug, different patient;US-PFIZER INC-202300276250 Same reporter/event/drug, different patient;; Reported Cause(s) of Death: 7 people had  died from Pfizer
Under recommended age for J&J vaccine.  Has been requested to enter all COVID vaccines. The teams responsible for screening and administering vaccines to the refugees. Assisting with entering information into  and VAERS.
Confusion, Headache, NauseaVomiting, Started with a euphoria feeling, now feeling very nauseous, has a pounding headache, and her mental clarity absent Narrative:  Other Relevant History:
Difficulty breathing, unable to swallow, throat swelling, heart pounding and beating really fast and hard, really severe headache, unable to see properly- vision blurred, itching all over my body, fainted, difficulty walking my feet felt really heavy, my hands were very shaking
itchiness at the injection site; swelling at the injection site; redness at the injection site; spread as a rash over shoulder and chest/Skin rash; This non-serious case was reported by a consumer via call center representative and described the occurrence of injection site itching in a 52-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 09-APR-2023, the patient received the 1st dose of Shingrix (intramuscular, right arm). On 10-APR-2023, 1 days after receiving Shingrix, the patient experienced injection site itching (Verbatim: itchiness at the injection site), injection site swelling (Verbatim: swelling at the injection site), injection site erythema (Verbatim: redness at the injection site) and rash (Verbatim: spread as a rash over shoulder and chest/Skin rash). The outcome of the injection site itching, injection site swelling, injection site erythema and rash were resolved (duration 10 days).   It was unknown if the reporter considered the injection site itching, injection site swelling, injection site erythema and rash to be related to Shingrix.   It was unknown if the company considered the injection site itching, injection site swelling, injection site erythema and rash to be related to Shingrix.   Additional Information: GSK Receipt Date: 09-MAY-2023 The reporter was a patient's daughter. The reporter stated that the patient received Shingrix and a day after developed redness, swelling and itchiness at the injection site that spread as a rash over shoulder and chest. The symptoms lasted for 10 days.  In April 2023, the patient was recovered from redness, swelling and itchiness at the injection site and skin rash. The reporter consented to follow up.
I got Covid on July 15th and now have one covid. Had 2 5 day hospital stays and 1 emergency visit. Emergency Room ? 7-17-22 - Pneumonia in ¼ of right lung ? Released same day Emergency Room ? Fainted ? 7-30-22 Pulmonary Atrial Hypertension. Cat Scan of lungs with contrast. - Transfer to a second facility ICU 7-31-22.  27 clots removed from lungs and screen put in heart 8-2-22 - Released from the ICU 8-3-22 The second facility - 10/31 to 11/4 Chest Cat Scan w/wo ? 7 bags magnesium
weak spells-w/diaphoresis;no appetite x 4 days;SOB
Irregular heartbeat, fatigue, shortness of breath - ER - heartblock   May not have anything to do with vaccine...
He developed shingles less than 1 month after 1st dose of SHINGRIX.
Info has been received from an RN concerning an 18 month old female who on 10/15/04 was vaccinated, SC with a 0.5 ml dose of varicella virus vaccine live. The RN reported, that on the morning of 4/8/05, the pt developed chickenpox characterized by a rash consisting of red, raised pustules. The RN indicated that the pt was not feeling well when the lesions appeared. The pt was noted to have 2 lesions on her hand between the index finger and thumb, a few on her chest and about 6 on her face. The lesions were noted not to be itchy and no fever was reported. Unspecified medical attention was sought and the pt was advised of the "usual varicella precautions and treatment". At the time of this report, the pt's chickenpox persisted. Th RN also reported that she had seen a few other cases of breakthrough. Additional info has been requested.
PATIENT EXPERIENCES BRIEF FAINTING SPELL AND RECOVERED QUICKLY, NAUSEA AND MINIMAL VOMITING DID FOLLOW. PATIENT DID RECOVER WITHIN ABOUT 15 MINUTES.  PATIENT REFUSED TO HAVE 911 CALLED AND IS TO BE CARED FOR FURTHER AT HOME AND BY PRIMARY PHYSICAN.
21 days between doses; A spontaneous report was received from a nurse concerning a 76-year-old male patient who received his second dose of mRNA-1273 21 days after his first dose.  The patient's medical history was not provided. Concomitant product use was not provided.  On 28 Jan 2021, prior to the onset of the event, the patient received the first of two planned doses of mRNA-1273 Batch number not provided) (site and route not provided) for prophylaxis of Covid 19 infection.  On 18 Feb 2021, the patient received the second of two planned doses of mRNA-1273 (Batch number 010M20A) intramuscularly into his left arm for prophylaxis of Covid-19 infection.   The patient was a resident at the reporter's facility (name not provided). The reporter, the patient's nurse, is concerned that the second dose was administered 21 days after the first dose. The nurse inquired whether there is information about delays longer than recommended between doses.  The patient received both scheduled doses of mRNA-1273 therefore action taken with the drug in response to the event is not applicable.  The event 21 days Between Doses outcome was considered resolved.; Reporter's Comments: This report refers to a case of  Product administration error  Inappropriate schedule of product administration for mRNA-1273, lot # unknown/010M20A with no associated AEs.
It started as small itchy bumps on my right arm at elbow. Progressed to welps and finally a rash over my right arm. It never moved beyond the arm. I googled when I realized it was my vaccine arm. I have had allergic reactions before, but this was limited to my right arm. Found a condition called COVID Arm.
3 to 4 days after vaccine administration, left arm became sore with a nickel-sized knot.  After three weeks, knot is still there and the area is sore.  Did not feel feverish or tired.  Patient put ice on area yesterday.  This is not the first flu vaccine that the client received. She denies being allergic to eggs.